Table 1.
Progression type and survival per treatment arm
| Treatment | Placebo RT/TMZ |
Bevacizumab RT/TMZ |
Placebo RT/TMZ |
Bevacizumab RT/TMZ |
Placebo RT/TMZ |
Bevacizumab RT/TMZ |
|---|---|---|---|---|---|---|
| PFS | OS | PPS | ||||
| Median, mo (95% CI) | Median, mo (95% CI) | Median, mo (95% CI) | ||||
| Progression type | ||||||
| Classic T1 | 6.0 (5.3, 6.6) | 7.9 (6.9, 9.2) | 16.8 (15.1, 19.1) | 14.2 (12.0, 15.1) | 9.6 (7.8, 11.0) | 5.7 (4.2; 6.9) |
| cT1 relapse | 12.4 (10.0, 21.4) | 11.8 (10.4, 12.9) | 27.4(21.6, 40.7) | 17.8 (15.9, 20.5) | 13.9 (7.9, 14.9) | 6.2 (5.0;7.5) |
| T2 diffuse | 26.2 (19.4, _._*) | 29.2 (18.9, 30.9) | _._ *(23.9, _._*) | _._* | 5.6 (1.7, 18.6) | 7.6 (4.4; _._*) |
| T2 circumscribed | 10.4 (5.1, 18.2) | 9.0 (7.9, 10.0) | 18.9 (10.2, 27.2) | 13.6 (12.1, 15.2) | 5.9 (2.9, 9.1) | 3.8 (2.7;5.0) |
| Primary nonresponder | 2.3 (2.2, 2.3) | 2.8 (2.1, 3.2) | 9.9 (7.9, 13.0) | 9.6 (3.5, 12.3) | 6.8 (5.2, 10.9) | 4.7 (0.6;8.0) |
Note: Median time from start of treatment until PFS and OS differed between the individual PTs in univariate analysis. In contrast to PFS and OS, no difference in PPS was detected between the PTs. Due to the post hoc setting, no P-values are provided. *Median OS not reached due to data acquisition closure. PFS = progression-free survival, OS = overall survival, PPS = post-progression survival.